Estelamari Rodriguez, MD, MPH, is the associate director of community outreach for thoracic oncology and the assistant director of diversity, equity, & inclusion at the University of Miami Sylvester ...
The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH. Based on data from the Beamion LUNG-1 ...
Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...
FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...
Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical Dermatology Conference. In an interview with The American Journal of Managed Care, ...
In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists ...
Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...
Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...
Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...
Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.
Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce ...
Data analysis reveals a stable, cross-cohort female cancer mortality excess at ages 35-60, contrasting with female advantages in cardiovascular and external-cause mortality. Breast cancer drives the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results